MENU
Friday, April 23rd, 2PM EDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Practically speaking about lupus anticoagulants and women's health: Part 1 of a series to learn about a paradoxical problem

Sponsored by: Diagnostica Stago, Inc.
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Dir. Scientific Affairs Market Access Group
    Biography

      Daniel A Kaczor graduated in June of 1980 from Utica College of Syracuse University where he earned his Bachelor's in Science in Medical Technology. He became board certified by the College of American Pathologists in August of 1980. Dan's entire professional career has been dedicated to the field of Hemostasis and Thrombosis. His tenure with Stago encompasses the last 28 years. He is currently the Director, Scientific Affairs, Market Access Group for Stago. Prior to this, he was the Director, Advanced Support Group, a department that encompassed hotline, customer/employee technical training, second level support and clinical and scientific research. Upon joining Stago, he held the position of Director, Technical Service Department. Before joining Stago, Dan spent 14 years in clinical laboratory medicine either as a Coagulation Specialist or as Supervisor of the Coagulation Department. He is the developer of the Platelet Neutralization Procedure and the 4 to 1 APTT Mixing Study, two tests that are performed globally for the detection of Lupus Anticoagulants. His 40-year career has been highlighted by numerous National as well as International publications and speaking engagements related to Hemostasis and Thrombosis.

    • Technical Support Specialist - Diagnostica Stago Inc.
      Biography

        Katy Whelchel has worked at Diagnostica Stago since 2001. Her roles at Stago have included Technical Support Specialist, Advanced Support Group, Clinical Research Associate and Technical Sales Representative. Previously she was Laboratory Supervisor at St. Mary's Hospital in Rogers, Arkansas. She was Hematology Clinical Instructor for University of Arkansas Medical Sciences' Medical Technology Program, as well as a member of the Mercy System Hematology/Coagulation Standardization Committee. Katy is co-author of five coagulation publications, a member of 3 CLSI Committees, and gives many presentations on Coagulation topics each year throughout the United States. In her spare time, she and her husband ride their motorcycle throughout the continental US. Katy is also an avid reader, and English Handbell aficionado.


      Abstract

      Practically speaking about lupus anticoagulants and women's health:
      Part 1 of a series to learn about a paradoxical problem

      Lupus anticoagulants are consistently present in patients at risk of thrombosis as a result of underlying antiphospholipid syndrome (aPS), a dangerous disorder treated by prophylactic anticoagulation using well-established methods. Our webinar, part of an ongoing series will give an overview of antiphospholipid syndrome, available clotting-based methods, validation procedures, and link in relevance to women’s health. The information provided will bring together different pieces of the overall but paradoxical picture of aPS, allowing for a full picture of the relevance in the overall care pathway.

       

      Learning Objectives

      1. Provide overview of lupus anticoagulants assays with emphasis not only on overall methods but commonly performed validation procedures
      2. Present linkage of lupus anticoagulants to patient care pathway for confirmed aPS patients
      3. Demonstrate relevance of aPS to real life patient situations

      Show Resources
      You May Also Like
      FEB 24, 2021 10:00 AM PST
      C.E. CREDITS
      FEB 24, 2021 10:00 AM PST
      DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
      DEC 03, 2020 4:30 PM PST
      C.E. CREDITS
      DEC 03, 2020 4:30 PM PST
      This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
      JAN 21, 2021 8:00 AM PST
      JAN 21, 2021 8:00 AM PST
      Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      NOV 05, 2020 7:00 AM PST
      C.E. CREDITS
      NOV 05, 2020 7:00 AM PST
      DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      Loading Comments...
      Show Resources
      Event Countdown
      • 0 Days
      • 0 Hours
      • 0 Minutes
      • 0 Seconds
      Attendees
      • See more